Search

Your search keyword '"Xu, Biao"' showing total 24 results
Start Over Author "Xu, Biao" Journal ssrn electronic journal
24 results on '"Xu, Biao"'

4. Magnifying Image Enhanced Endoscopy Only Model (MIEEo) Boosted the Diagnostic Efficiency of Early Cancer and Precancerous Lesions in Upper Gastrointestinal Tract：A Multicenter Randomized Controlled Trial

Author

Ai-Rui Jiang, Li-Ming Wen, Jianwei Ding, Rui-Zheng Zou, Xu-Biao Nie, Jing Chen, Wei-Sen Zhang, Liang-Ying Dan, Yu-Xia Zhu, Chun-Mei Ren, Hui Lin, Ying-Yang Wu, Lin-Lin Sheng, Ding-Rong Chen, Guo-Bin Liao, Hai-Yan Zhao, Jian-Jun Li, Ying Zuo, Jie Chen, Shuang Yu, Liang-Bi Xu, and Jianying Bai

Subjects
History, Polymers and Plastics, Business and International Management, Industrial and Manufacturing Engineering
Published
2022

5. Magnifying Image Enhanced Endoscopy Only Model (MIEEo) Boosted the Diagnostic Efficiency of Early Cancer and Precancerous Lesions in Upper Gastrointestinal Tract：A Multicenter Randomized Controlled Trial

Author

Jiang, Ai-Rui, primary, Wen, Li-Ming, additional, Ding, Jianwei, additional, Zou, Rui-Zheng, additional, Nie, Xu-Biao, additional, Chen, Jing, additional, Zhang, Wei-Sen, additional, Dan, Liang-Ying, additional, Zhu, Yu-Xia, additional, Ren, Chun-Mei, additional, Lin, Hui, additional, Wu, Ying-Yang, additional, Sheng, Lin-Lin, additional, Chen, Ding-Rong, additional, Liao, Guo-Bin, additional, Zhao, Hai-Yan, additional, Li, Jian-Jun, additional, Zuo, Ying, additional, Chen, Jie, additional, Yu, Shuang, additional, Xu, Liang-Bi, additional, and Bai, Jianying, additional

Published
2022
Full Text
View/download PDF

16. The Artificial i NTelligence-Assisted sm All bow L caps Ule endo Scopy ( TANTALUS), Multicentre Study – AI in Capsule Well within Our Reach

Author

Xie, Xia, primary, Xiao, Yu-Feng, additional, Li, Jian-Jun, additional, Yang, Qiang-Qiang, additional, Peng, Xue, additional, Nie, Xu-Biao, additional, Zhou, Jian-Yun, additional, Zhao, Yong-Bing, additional, Yang, Huan, additional, Liu, Xi, additional, Liu, En, additional, Chen, Yu-Yang, additional, Zhou, Yuan-Yuan, additional, Fan, Chao-Qiang, additional, Bai, Jian-Ying, additional, Zhao, Xiao-Yan, additional, Koulaouzidis, Anastasios, additional, Lin, Hui, additional, and Yang, Shiming, additional

Published
2021
Full Text
View/download PDF

19. Comparing Effectiveness of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review and Network Meta-Analysis

Author

Hai-Bin Tu, Meng-Chao Wu, Shi-Peng Chen, Yuzhen Gao, Zhen-Hua Chen, Wan Yee Lau, Xiu-Ping Zhang, Jie Shi, Zong-Tao Chai, Kang Wang, Shu-Qun Cheng, Xu-Biao Wei, Xin-Xin Ye, and Wei-Xing Guo

Subjects
Sorafenib, medicine.medical_specialty, business.industry, Portal vein, Odds ratio, Cochrane Library, medicine.disease, Multidisciplinary approach, Internal medicine, Hepatocellular carcinoma, Meta-analysis, Medicine, Liver function, business, medicine.drug
Abstract

Background: Several multidisciplinary treatment strategies are now available to treat hepatocellular carcinoma (HCC) and portal vein tumour thrombus (PVTT). However, most of these studies were not powered to test the differences in overall survival (OS). Methods: The PubMed, Cochrane Library, Web of Science and Embase were searched to identify both the direct and indirect evidence for these treatments on patients with HCC and PVTT up to December 31, 2017. A Bayesian random-effects model was used to combine direct with indirect evidence. Results: After screening 1675 citations, 54 trials included 11311 participants and 8 multidisciplinary treatments. The tests of inconsistency and heterogeneity for the network meta-analysis showed the P-values of global inconsistency to range from 0.4012 to 0.6972, and the I2 values to range from 0% to 7% for the 1-, 2-, 3- and 5-year overall survival (OS) rates. After adjusting the network model by Bayesian meta-analysis with clinical variables, a stable ranking of eight treatments was achieved. The results showed that patients who received Sorafenib (SURCA=35.1) was not better than the other treatments. Comprehensive treatments based on surgery (CST) had better OS rates than patients who received other treatments (SURCA =89.6 and the odds ratio (OR) to range from 1.39 to 108.44). Conclusion: CST significantly improved OS when compared with sorafenib and other multidisciplinary treatments, especially in selected HCC patients with PVTT limited to a first-order branch or above of the main portal vein, and with good liver function. Funding Statement: This work is supported by these funding sources as following: the Key Project of Natural Science Foundation of China (No: 81730097); the grants of the Science Fund for Creative Research Groups (No: 81521091); Chang Jiang Scholars Program (2013) of the China Ministry of Education; the National Key Basic Research Program “973 project” (No: 2015CB554000); the National Natural Science Foundation of China (No: 81602523 and No: 81702335) Declaration of Interests: The authors declare that they have no conflicts of interest. Ethics Approval Statement: This study has been registered with PROSPERO under the number CRD42018104670.

Published
2019

20. A New Staging System for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombus

Author

Lei Guo, Minshan Chen, Li Xu, Yaxin Zheng, Xiu-Ping Zhang, Shu-Qun Cheng, Yuzhen Gao, Wei-Dong Jia, Li-Ping Zhou, Le-Qun Li, Kang Wang, Xiaolong Qi, Meng Wang, Meng-Chao Wu, Ju-Xian Sun, Wan Yee Lau, Tian-Fu Wen, Chongde Lu, Xu-Biao Wei, Wei-Xing Guo, Jie Xue, and Jie Shi

Subjects
medicine.medical_specialty, Multivariate analysis, business.industry, General surgery, Portal vein, Declaration, medicine.disease, Tumor thrombus, Hepatocellular carcinoma, Medicine, Liver function, Stage (cooking), business, Staging system
Abstract

Background. BCLC C stage does not identify patients homogeneous enough to be allocated to a single stage. A new staging system for patients with hepatocellular carcinoma (HCC) associated with portal vein tumor thrombus (PVTT) was developed by incorporating the good points of the BCLC classification of HCC, and by improving on the currently existing classifications of HCC with PVTT. Methods. Univariate and multivariate analysis with Wald χ2 test were used to determinate the clinical prognostic factors for overall survival (OS) in patients with HCC and PVTT in the training cohort. Then the conditional inference trees analysis was applied to establish a new staging system. Results. A training cohort of 2179 patients from the Eastern Hepatobiliary Surgery Hospital and a validation cohort of 1550 patients from four major liver centers in China were enrolled into establishing and validating a new staging system. The system was established by incorporating liver function, general health status, tumor resectability, extrahepatic metastasis and extent of PVTT. The median OS were 57.1 (37.2-76.9), 12.1 (11.0-13.2), 5.7 (5.1-6.2), 4.0 (3.3-4.6) and 2.5 (1.7-3.3) months for the stages 0 to IV, respectively (p

Published
2019

21. Comparing Effectiveness of Multidisciplinary Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review and Network Meta-Analysis

Author

Zhang, Xiu-Ping, primary, Chen, Zhen-Hua, additional, Gao, Yu-Zhen, additional, Ye, Xin-Xin, additional, Wei, Xu-Biao, additional, Wang, Kang, additional, Chai, Zong-Tao, additional, Shi, Jie, additional, Guo, Wei-Xing, additional, Chen, Shi-Peng, additional, Tu, Hai-Bin, additional, Wu, Meng-Chao, additional, Lau, Wan Yee, additional, and Cheng, Shu-Qun, additional

Published
2019
Full Text
View/download PDF

22. A New Staging System for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombus

Author

Lau, Wan Yee, primary, Wang, Kang, additional, Zhang, Xiu-Ping, additional, Li, Le-Qun, additional, Wen, Tian-Fu, additional, Chen, Min-Shan, additional, Jia, Wei-Dong, additional, Xu, Li, additional, Shi, Jie, additional, Guo, Wei-Xing, additional, Sun, Ju-Xian, additional, Guo, Lei, additional, Wei, Xu-Biao, additional, Lu, Chong-De, additional, Xue, Jie, additional, Zhou, Li-Ping, additional, Zheng, Ya-Xin, additional, Wang, Meng, additional, Gao, Yu-Zhen, additional, Qi, Xiao-Long, additional, Wu, Meng-Chao, additional, and Cheng, Shu-Qun, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results